Sirio Pharma Co., Ltd. (SHE:300791)

Sirio Pharma Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	4,186	4,184	3,568	2,493	2,331	2,029
Other Revenue	27.4	27.4	13.91	14.19	38.01	37.42
Revenue	4,214	4,211	3,582	2,507	2,369	2,067
Revenue Growth (YoY)	9.98%	17.56%	42.87%	5.84%	14.62%	30.85%
Cost of Revenue	2,870	2,891	2,498	1,737	1,604	1,405
Gross Profit	1,344	1,320	1,085	770.42	764.94	661.56
Selling, General & Admin	807.92	770.86	628.44	428.27	385.27	306.64
Research & Development	124.25	125.94	110.49	80.72	83.19	64.71
Other Operating Expenses	-7.38	-6.48	-35.8	14.85	14.4	12.82
Operating Expenses	923.29	890.64	708.19	527.83	483.83	387.71
Operating Income	420.96	429.2	376.33	242.59	281.11	273.85
Interest Expense	-101.62	-95.03	-78.48	-42.77	-13.93	-1.8
Interest & Investment Income	8.35	6.89	9.24	34.97	32.18	20.33
Currency Exchange Gain (Loss)	10.86	10.86	20.31	25.49	-18.17	-3.96
Other Non Operating Income (Expenses)	0.52	-2.87	-1.28	-1.47	-1.25	-1.6
EBT Excluding Unusual Items	339.07	349.05	326.11	258.81	279.96	286.82
Gain (Loss) on Sale of Investments	-23.04	-26.72	-57.67	-1.64	-1.05	3.95
Gain (Loss) on Sale of Assets	-0.06	0.24	0.03	-5.51	0.15	-0.01
Asset Writedown	-2.38	-4.41	-0.95	-	-1.86	-1.39
Other Unusual Items	-1.41	-1.51	5.73	-0.15	3.7	22.59
Pretax Income	312.19	316.65	273.26	251.52	280.9	311.96
Income Tax Expense	27.56	34.64	32.97	39.23	49.07	54.6
Earnings From Continuing Operations	284.63	282.02	240.29	212.29	231.83	257.37
Minority Interest in Earnings	46.04	43.04	40.75	-	-	-
Net Income	330.67	325.06	281.04	212.29	231.83	257.37
Net Income to Common	330.67	325.06	281.04	212.29	231.83	257.37
Net Income Growth	5.09%	15.66%	32.39%	-8.43%	-9.92%	80.58%
Shares Outstanding (Basic)	303	304	305	304	304	304
Shares Outstanding (Diluted)	303	304	305	307	322	306
Shares Change (YoY)	-0.65%	-0.36%	-0.82%	-4.47%	5.00%	23.77%
EPS (Basic)	1.09	1.07	0.92	0.70	0.76	0.85
EPS (Diluted)	1.09	1.07	0.92	0.69	0.72	0.84
EPS Growth	5.77%	16.08%	33.48%	-4.15%	-14.21%	45.89%
Free Cash Flow	309.1	154.84	-65.62	151.17	-183.31	96.43
Free Cash Flow Per Share	1.02	0.51	-0.21	0.49	-0.57	0.32
Dividend Per Share	0.500	0.500	0.651	0.207	0.237	0.237
Dividend Growth	-23.18%	-23.18%	214.29%	-12.50%	-	200.00%
Gross Margin	31.90%	31.34%	30.28%	30.73%	32.29%	32.01%
Operating Margin	9.99%	10.19%	10.51%	9.68%	11.87%	13.25%
Profit Margin	7.85%	7.72%	7.85%	8.47%	9.79%	12.45%
Free Cash Flow Margin	7.33%	3.68%	-1.83%	6.03%	-7.74%	4.67%
EBITDA	594.31	612.03	597.06	366.95	379.29	353.57
EBITDA Margin	14.10%	14.53%	16.67%	14.64%	16.01%	17.11%
D&A For EBITDA	173.35	182.83	220.73	124.36	98.18	79.72
EBIT	420.96	429.2	376.33	242.59	281.11	273.85
EBIT Margin	9.99%	10.19%	10.51%	9.68%	11.87%	13.25%
Effective Tax Rate	8.83%	10.94%	12.06%	15.60%	17.47%	17.50%
Revenue as Reported	4,214	4,211	3,582	2,507	2,369	2,067
Advertising Expenses	-	12.17	7.8	11.73	31.9	11.26

Source: S&P Global Market Intelligence. Standard template. Financial Sources.